BioSpace News Archive

Intensity Therapeutics, Inc. announced the pricing of its upsized initial public offering of 3,900,000 shares of common stock at a public offering price of $5.00 per share.

Black Diamond Therapeutics, Inc. announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $5.00 per share.

Immunome and Morphimmune, a private biotechnology company focused on developing targeted oncology therapeutics, announced that they have entered into a definitive merger agreement.

Fresenius Kabi announced that its Ivenix® Infusion System has been selected by the Metrodora Institute to meet the Institute’s infusion medicine needs.

Inhibikase Therapeutics, Inc. today announced that it will effect a 1-for-6 reverse stock split of its common stock.

Alkermes plc announced that, at the Company’s 2023 Annual General Meeting of Shareholders, shareholders voted to re-elect all seven of Alkermes’ director nominees.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical

AlloSource® announced the Journal of Orthopaedic Surgery published the study titled “Short term clinical outcomes of a ProChondrix® thin laser-etched osteochondral allograft for the treatment of articular cartilage defects in the knee.” This study demonstrated encouraging patient-reported outcomes in the treatment of symptomatic articular cartilage lesions using a laser-etched osteochondral allograft, ProChondrix.

ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced today the publication of data in the NEJM Evidence, validating the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer.

Kiyatec, the leader in clinically correlated functional precision oncology, and XenoSTART, the worldwide leader in patient derived xenograft model development, have formally announced their ongoing collaboration to help biopharma more rapidly assess efficacy with XenoSTART’s Patient Derived Xenograft (XPDX) models, using Kiyatec’s ex vivo 3D spheroid screening platform.